Full-Time

Specialty Account Manager

Auvelity, Waterbury CT

Posted on 8/23/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Biopharmaceutical company developing CNS therapies

Compensation Overview

$100k - $150k/yr

+ Annual bonus + Equity

Waterbury, CT, USA

In Person

Category
Sales & Account Management (2)
,
Required Skills
Management
Requirements
  • Bachelor’s degree from an accredited college or university.
Responsibilities
  • Proficient in both virtual and live customer engagements.
  • Develop a comprehensive and effective territory business plan aimed at achieving and exceeding quarterly & annual goals established by commercial leadership.
  • Promote within our approved labeling in a comprehensive, fair, and ethical manner that is consistent with industry specific and corporate legal and regulatory guidelines.
  • Develop strong customer relationships by better understanding the customer’s needs.
  • Serve as a resource/consultant to customers and staff regarding payer policies and processes (i.e., eligibility and benefit verification, prior-authorization, and appeals/denials).
  • Maximize use of marketing resources to maintain and develop customer relationships for the purpose of growing the customers’ confidence to prescribe Axsome medications for appropriate patients.
  • Communicate territory activity in an accurate and timely manner as directed by management.
  • Provide feedback to sales and commercial leadership, colleagues, marketing, and other internal departments about changing environment and results.
  • Successfully complete all training classes in a timely manner.
  • Complete administrative duties in an accurate and timely fashion.
  • Manage efforts within assigned promotional budget.
  • Effectively collaborate across all corporate functions.
  • Attend medical congresses and society meetings as needed.
  • Ensure timely access for patients through patient services and savings programs.
  • Overnight travel as indicated by the needs of the business.
  • Additional responsibilities as assigned.
Desired Qualifications
  • Launch experience strongly preferred.
  • Psychiatry/Central Nervous System experience strongly preferred.
  • Patient support services experience a plus.
  • Strong digital marketing aptitude
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders and focuses on research, development, and commercialization of medicines. Its lead product candidate, AXS-05, is an oral NMDA receptor antagonist being developed to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The company moves its pipeline through clinical trials and regulatory approvals to bring therapies to patients and earns revenue from drug sales, partnerships, and licensing. It differentiates itself by pursuing CNS-focused therapies with NMDA receptor targets and by pursuing designations like FDA Breakthrough Therapy to speed development, with a goal of improving patient outcomes and quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Auvelity Q1 2026 revenue hit $153.2M, up 59%, with $8B peak sales outlook post-Alzheimer's approval.
  • Total Q1 2026 revenue reached $191M, up 57%, beating estimates via sales force expansion.
  • Pipeline advances with AXS-12 NDA submission and AXS-20 addition for schizophrenia.

What critics are saying

  • Symbravo loses share to generic triptans and gepants due to high FDC pricing in 6-12 months.
  • AXS-12 NDA fails FDA approval from weak Phase III data, dropping stock 30-50% in 12-18 months.
  • Cash burns $305M reserves from sales force doubling before profitability in 18-24 months.

What makes Axsome Therapeutics Inc unique

  • Auvelity targets NMDA receptors for MDD and Alzheimer's agitation with FDA approvals.
  • Symbravo combines meloxicam-rizatriptan for acute migraine with long-term MOVEMENT trial benefits.
  • Sunosi treats narcolepsy daytime sleepiness with expanding Phase 3 indications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Yahoo Finance
Apr 8th, 2026
Axsome Therapeutics surges 33% annually since 2015 IPO, eyes $16B peak sales

Axsome Therapeutics, a midcap biotech, has delivered a compound annual growth rate of 33.32% since its 2015 IPO, potentially turning a $50,000 investment into nearly $1 million. However, replicating this performance over the next decade would require the company to reach a market capitalisation of approximately $157 billion. The company's 2025 revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity, a depression treatment. Auvelity may soon receive approval for treating agitation in Alzheimer's disease, expanding its addressable market to over five million US patients. Axsome Therapeutics' pipeline includes several phase 3 assets targeting over 150 million patients, with predicted peak sales exceeding $16 billion. Whilst the company shows promise for long-term growth through the 2040s, matching its historical performance remains unlikely.

Bitget
Mar 18th, 2026
Superstring Capital invests $6.84M in CNS pharma Axsome Therapeutics, stock up 27%

Superstring Capital Management invested $6.84 million in Axsome Therapeutics, purchasing 37,433 shares during Q4 2025, according to a SEC filing dated 17 February 2026. The investment represents nearly 4% of the fund's reported 13F assets. Axsome Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for central nervous system conditions including major depressive disorder, migraines and narcolepsy. The company has commercialised several treatments and recently launched a Phase 3 trial for solriamfetol in major depressive disorder with excessive daytime sleepiness. Axsome shares traded at $158.40 on Wednesday, up 27% over the past year, outpacing the S&P 500's 19% gain. The company reported $638.5 million in annual revenue, a 66% increase from 2024, with a market capitalisation of $8.1 billion.

Yahoo Finance
Mar 18th, 2026
Superstring Capital bets $6.8M on CNS drugmaker Axsome as Phase 3 trial begins and shares climb 27%

Superstring Capital Management has disclosed a new $6.84 million position in Axsome Therapeutics, acquiring 37,433 shares during the fourth quarter of 2025. The stake represents nearly 4% of the fund's assets under management. Axsome Therapeutics, a biopharmaceutical company specialising in central nervous system disorder treatments, has seen its shares rise 27% over the past year to $158.40. The company generated $638.5 million in revenue over the trailing twelve months, representing 66% growth from 2024. The company markets therapies for depression, migraine and sleep disorders whilst advancing a late-stage pipeline. Axsome recently initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, a segment with no approved treatments currently available.

Yahoo Finance
Mar 12th, 2026
Axsome's Auvelity surpasses $500M revenue, eyes approval for Alzheimer's agitation by April

Axsome Therapeutics reported Auvelity surpassed $500 million in revenue during its third year, with total company sales approaching $640 million in 2025. Auvelity posted approximately 68% year-over-year growth. The company's supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease agitation is under priority review, with a PDUFA date of 30 April 2026. This represents Axsome's key near-term regulatory catalyst, supported by three positive trials. Axsome is doubling its field force from 300 to 600 representatives by Q2, ahead of a potential launch. The company is advancing seven Phase III trials across multiple indications whilst maintaining approximately $323 million in cash to fund operations.

Yahoo Finance
Mar 6th, 2026
Axsome doubles salesforce to 600 reps as AUVELITY hits $155M quarter ahead of April Alzheimer's decision

Axsome Therapeutics reported $155 million in quarterly revenue for AUVELITY, annualising over $600 million just 13 quarters post-launch, though market penetration remains at approximately 0.2% of the antidepressant market. The company plans to double its salesforce from 300 to 600 representatives to drive uptake and support a potential Alzheimer's agitation launch. Over 50% of AUVELITY prescriptions are now monotherapy, with roughly 15% first-line and 35% first-switch therapy. Primary care clinicians account for about 30% of prescribers. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with an FDA decision expected on 30 April. Management reported revenue growth outpacing operating expenses by 3-to-1 in 2025, demonstrating strong operating leverage despite increased direct-to-consumer spending.

INACTIVE